Subsequent Entry Biologics
Biologic drugs represented a major step forward in treating inflammatory arthritis, including ankylosing spondylitis and rheumatoid arthritis. Rather than being developed from chemistry, these complex medications are made from living organisms.
Now, as biologics come off patent, subsequent entry biologics (SEBs) are set to further alter this arthritis treatment landscape. SEBs are an extension of this breakthrough therapy, also developed with living cells, and they will provide more treatment choices for Canadians with arthritis.
SEBs are new drugs, not “generic” drugs, and one key issue is what their chemical names will be. For this and other issues, The Society has published a position paper [PDF]
to help inform patients, doctors, drug plans and regulators – as well as these two resources of the more visual variety:
Dr. Leigh Revers of the University of Toronto explains what 'subsequent entry biologics' are, and what people with arthritis need to know about them (6:45)